November 7, 2022
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022
March 4, 2022
FierceBiotech
A2 Bio’s Activator-blocker CAR-T Cell Therapies Show Early Promise in Solid Cancers
March 2, 2022
A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select Patients
January 18, 2022
A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future TmodTM CAR T Therapy
November 12, 2021
A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021
November 1, 2021
A2 Bio to Highlight Program Updates in Two Presentations at SITC 2021
January 13, 2021
Tempus Announces Companion Diagnostic Collaboration with A2 Biotherapeutics
December 23, 2020
A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers
October 6, 2020
A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics
November 5, 2019
A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A to Develop a Pipeline of Selective Tumor Cell Therapeutics
